Long Kwei

595 total citations
16 papers, 215 citations indexed

About

Long Kwei is a scholar working on Oncology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Long Kwei has authored 16 papers receiving a total of 215 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Genetics and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Long Kwei's work include Chronic Lymphocytic Leukemia Research (6 papers), Multiple Myeloma Research and Treatments (4 papers) and Adenosine and Purinergic Signaling (3 papers). Long Kwei is often cited by papers focused on Chronic Lymphocytic Leukemia Research (6 papers), Multiple Myeloma Research and Treatments (4 papers) and Adenosine and Purinergic Signaling (3 papers). Long Kwei collaborates with scholars based in United States, Poland and United Kingdom. Long Kwei's co-authors include Milan R. Henzl, G. David Adamson, Richard A. Edgren, Richard A. Miller, Andrew Hotson, Mehrdad Mobasher, Jaime R. Merchan, John D. Powderly, Minal Barve and Jason J. Luke and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Long Kwei

16 papers receiving 208 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Long Kwei United States 8 73 62 62 52 48 16 215
Cunjian Yi China 9 30 0.4× 44 0.7× 44 0.7× 19 0.4× 84 1.8× 26 194
Clare Bartos United Kingdom 9 132 1.8× 74 1.2× 66 1.1× 25 0.5× 92 1.9× 13 246
Beata Maćkowiak-Matejczyk Poland 8 125 1.7× 96 1.5× 66 1.1× 39 0.8× 57 1.2× 14 243
Julia Perkins Smith United States 5 74 1.0× 152 2.5× 14 0.2× 73 1.4× 87 1.8× 12 253
Tong Shu China 8 37 0.5× 87 1.4× 29 0.5× 15 0.3× 174 3.6× 22 251
María Luisa Palacios‐Berraquero Spain 5 68 0.9× 64 1.0× 50 0.8× 18 0.3× 45 0.9× 8 177
Eva María Guerra Alia Spain 7 118 1.6× 127 2.0× 28 0.5× 15 0.3× 46 1.0× 15 183
Zimin Pan China 9 78 1.1× 62 1.0× 67 1.1× 10 0.2× 59 1.2× 25 235
Chunyan Wei China 12 58 0.8× 38 0.6× 75 1.2× 145 2.8× 162 3.4× 19 342
Jitka Hausnerová Czechia 10 84 1.2× 70 1.1× 63 1.0× 23 0.4× 142 3.0× 37 297

Countries citing papers authored by Long Kwei

Since Specialization
Citations

This map shows the geographic impact of Long Kwei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Long Kwei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Long Kwei more than expected).

Fields of papers citing papers by Long Kwei

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Long Kwei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Long Kwei. The network helps show where Long Kwei may publish in the future.

Co-authorship network of co-authors of Long Kwei

This figure shows the co-authorship network connecting the top 25 collaborators of Long Kwei. A scholar is included among the top collaborators of Long Kwei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Long Kwei. Long Kwei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Johnson, Melissa L., Chun‐Gon Kim, A. W. Tolcher, et al.. (2024). 501LBA LBA Orals: Phase 1 expansion results of IDE397, a first-in-class, oral, MAT2A inhibitor (MAT2Ai) in MTAP deleted(del) non-small cell lung cancer (NSCLC) and urothelial cancer (UC). European Journal of Cancer. 211. 114979–114979. 1 indexed citations
2.
3.
Harshman, Lauren C., Michael P. Chu, Saby George, et al.. (2020). Adenosine receptor blockade with ciforadenant +/- atezolizumab in advanced metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 38(6_suppl). 129–129. 23 indexed citations
4.
Luke, Jason J., John D. Powderly, Jaime R. Merchan, et al.. (2019). Immunobiology, preliminary safety, and efficacy of CPI-006, an anti-CD73 antibody with immune modulating activity, in a phase 1 trial in advanced cancers.. Journal of Clinical Oncology. 37(15_suppl). 2505–2505. 36 indexed citations
5.
Mobasher, Mehrdad, Richard A. Miller, Long Kwei, et al.. (2019). A phase I/Ib multicenter study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent, in combination with CPI-444, and in combination with pembrolizumab in adult patients with advanced cancers.. Journal of Clinical Oncology. 37(15_suppl). TPS2646–TPS2646. 7 indexed citations
6.
Richardson, Paul G., William Bensinger, Carol Ann Huff, et al.. (2018). Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. British Journal of Haematology. 180(6). 821–830. 30 indexed citations
7.
Willingham, Stephen B., Andrew Hotson, Ginna G. Laport, et al.. (2018). Identification of adenosine pathway genes associated with response to therapy with the adenosine receptor antagonist CPI-444. Annals of Oncology. 29. viii403–viii404. 7 indexed citations
8.
9.
Flinn, Ian W., Nathan Fowler, Long Kwei, et al.. (2017). PHASE 3 STUDY OF IBRUTINIB IN COMBINATION WITH RITUXIMAB VERSUS PLACEBO IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH TREATMENT‐NAÏVE FOLLICULAR LYMPHOMA (PERSPECTIVE). Hematological Oncology. 35(S2). 427–428. 1 indexed citations
10.
11.
Chhabra, Saurabh, Saad Z. Usmani, Sarah M. Larson, et al.. (2015). The Bruton's tyrosine kinase inhibitor ibrutinib in combination with carfilzomib in patients with relapsed or relapsed and refractory multiple myeloma: initial results from a multicenter phase 1/2b study. Clinical Lymphoma Myeloma & Leukemia. 15. e275–e276. 1 indexed citations
12.
Richardson, Paul G., Jack W. Singer, Carol Ann Huff, et al.. (2015). Ibrutinib in combination with low-dose dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: results from a multicenter phase 2 trial. Clinical Lymphoma Myeloma & Leukemia. 15. e80–e81. 2 indexed citations
13.
Posey, James, Peter Johnson, Tony Mok, et al.. (2005). Results of a phase 2/3 open-label, randomized trial of T138067 versus doxorubicin (DOX) in chemotherapy-naïve, unresectable hepatocellular carcinoma (HCC). Journal of Clinical Oncology. 23(16_suppl). 4035–4035. 18 indexed citations
14.
Adamson, G. David, W L Heinrichs, Milan R. Henzl, et al.. (1997). Therapeutic efficacy and bone mineral density response during and following a three-month re-treatment of endometriosis with nafarelin (Synarel). American Journal of Obstetrics and Gynecology. 177(6). 1413–1418. 14 indexed citations
15.
Adamson, G. David, Long Kwei, & Richard A. Edgren. (1994). Pain of endometriosis: effects of nafarelin and danazol therapy.. PubMed. 39(4). 215–7. 30 indexed citations
16.
Henzl, Milan R. & Long Kwei. (1990). Efficacy and safety of nafarelin in the treatment of endometriosis. American Journal of Obstetrics and Gynecology. 162(2). 570–574. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cunjian Yi Breakdown of academic impact, for papers by Clare Bartos Breakdown of academic impact, for papers by Beata Maćkowiak-Matejczyk Breakdown of academic impact, for papers by Julia Perkins Smith Breakdown of academic impact, for papers by Tong Shu Breakdown of academic impact, for papers by María Luisa Palacios‐Berraquero Breakdown of academic impact, for papers by Eva María Guerra Alia Breakdown of academic impact, for papers by Zimin Pan Breakdown of academic impact, for papers by Chunyan Wei Breakdown of academic impact, for papers by Jitka Hausnerová
Rankless by CCL
2026